Research Article
KDELR3 Is a Prognostic Biomarker Related to the Immune Infiltration and Chemoresistance of Anticancer Drugs in Uveal Melanoma

Jingnan Zhang,1 Juan Zhang,2 Jing Guan,2 Lisha Yu,2 and Shilong Yan3

1Department of Pharmacy, Linyi Central Hospital, Linyi, Shandong, China
2Department of Traditional Chinese Medicine, Qingdao Eighth People’s Hospital, Qingdao, Shandong, China
3Department of Cataract, Jinan Aier Eye Hospital, Jinan, Shandong, China

Correspondence should be addressed to Shilong Yan; shilongy828@163.com

Received 27 June 2022; Revised 31 July 2022; Accepted 1 August 2022; Published 21 August 2022

Academic Editor: Fu Wang

Copyright © 2022 Jingnan Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Uveal melanoma (UM) is an intraocular malignancy in adults in which approximately 50% of patients develop metastatic diseases and have a poor clinical outcome. Immunotherapies are quickly becoming a need, and recent research has produced some amazing achievements in this area. In the current investigation, an attempt was made to evaluate the prognostic usefulness of KDELR3 in UM, particularly its connection with tumor-infiltrating lymphocytes (TILs). The expression patterns of mRNAs and related clinical data of 80 UM patients were obtained from The Cancer Genome Atlas (TCGA). By using RT-PCR, we were able to investigate whether or not UM cells and D78 cells expressed KDELR3. The Kaplan-Meier approach, as well as univariate and multivariate tests, was utilized in order to investigate the potential predictive significance of KDELR3 expression. The associations between KDELR3 and TILs and immunological checkpoints were analyzed in order to evaluate the effect that KDELR3 may have on UM immunotherapy. On the basis of the differential expression of KDELR3, a distribution of the half-maximal inhibitory concentration (IC50) of various targeted medicines was observed. In this study, we found that the expression of KDELR3 was distinctly increased in most types of tumors. In addition, KDELR3 was highly expressed in UM cells. Moreover, patients with high KDELR3 expression exhibited a shorter overall survival and disease-free survival than those with low KDELR3 expression. Multivariate analyses confirmed that KDELR3 expression was an independent prognostic factor for overall survival and disease-free survival in patients with UM. Furthermore, KDELR3 expression was demonstrated to be positively correlated with macrophage M1, T cell CD8, T cell follicular helper, dendritic cell resting, and T cell CD4 memory activated. Meanwhile, the expression of KDELR3 was related to several immune checkpoints. The IC50 of AP-24534, BHG712, bleomycin, camptothecin, cisplatin, cytarabine, GSK1070916, and tipifarnib was higher in the KDELR3 high-expression group. In conclusion, KDELR3 may be applied as a potential diagnostic and prognostic biomarker for UM patients.

1. Introduction

Uveal melanoma (UM) is the most prevalent form of intraocular cancer found in adults around the world [1]. It is a malignant tumor that begins in the melanocytes of the eye’s choroid plexus, iris, and ciliary body [2]. The development of early metastases is the primary contributor to the disease’ alarmingly high mortality rate [3, 4]. Because the biology behind the beginnings and spread of UM is unknown, there is currently no effective treatment available for patients who have already developed metastatic illness [5, 6]. It is estimated that almost half of UM patients will have further deterioration, and the clinical outcome for the patients remains poor [7]. The use of chemotherapy and targeted therapies typically does not result in the maintenance of long-term tumor control. Thus, immunotherapy is increasingly
emerging as a potentially useful treatment option [8, 9]. Meanwhile, it is essential to investigate potential new prognostic biomarkers or therapeutic targets that are effective.

The KDEL (Lys-Asp-Glu-Leu) receptor family, also known as the KDELR family, is an important protein family that plays a role in recycling the chaperones and maintaining the dynamic balance of trafficking between the Golgi and the endoplasmic reticulum (ER) [10, 11]. Recent researches have shown evidence to imply that KDELRs are essential components of the Golgi transport control mechanism. KDELR is responsible for initiating transport via the Golgi complex after it binds to the heterotrimeric signaling G protein G (q/11), where it then activates the proteins [12, 13]. The third confirmed member of the KDEL family is referred to as KDELR3. KDELR3 expression in arteriosclerosis macrophages might be noticeably different from that in nonarteriosclerosis tissues, and the higher expression level in nonarteriosclerosis tissues, which can be used as a potential predictive factor [14]. In addition, a number of investigations have found that the expression of KDELR3 was markedly aberrant in a variety of malignancies, including hepatocellular carcinoma and prostate adenocarcinoma [15, 16]. However, its expression and clinical significance in UM have not been investigated.

The vast majority of immune system components have been linked to both the beginning and the development of UM [17]. In the context of tumor immunity, tumor cells serve the function of antigens, and immune cells and leukocytes penetrate the tumor tissue via chemotaxis in order to mount an immunological defense [18, 19]. In addition, immune evasion is a significant contributor to the development of tumors. At the moment, a wide variety of novel immunotherapies are being utilized in UM, some of which are PD-1, PD-L1, and CTLA-4 inhibitors [20–22]. However, these methods are only useful for a small number of individuals, and the vast majority of patients have either a limited or nonexistent response to the treatment, particularly when the UM is in a more advanced stage. Therefore, in order to investigate the potential diagnostic application of new biomarkers, it is necessary to perform exhaustive studies on the association that exists between key genes and overall survival in UM.

In the present investigation, we began by conducting pan-cancer assays, and we discovered that the level of KDELR3 was noticeably elevated in the majority of different kinds of cancers. After that, we discovered that the level of KDELR3 expression was considerably elevated in UM cells. In addition, we investigated the expression of KDELR3 in UM and investigated the connection between the level of KDELR3 expression and the prognosis of patients with UM. Finally, exhaustive bioinformatics studies were carried out in order to investigate the underlying mechanisms of KDELR3. This study contributes to the following individualized diagnosis and treatment of UM by providing relevant information.

2. Materials and Methods

2.1. Cell Lines and Culture. The uveal melanoma cell lines (MUM-2C, OCM-1A, MUM-2B, and C918) and one melanocyte cell line (D78) were purchased from purchase Chinese Academy of Sciences (Beijing, China). DMEM was used as the medium for the cultivation of D78, OCM-1A, and MUM-2C, while RPMI 1640 was utilized for the upkeep of C918 and MUM-2B.

2.2. RNA Isolation and RT-PCR. Extraction of total RNAs from grown cells was carried out using TRIzol (Life Technologies) in accordance with the procedure provided by the manufacturer. cDNAs were reverse transcribed using HiScript III Reverse Transcriptase (Vazyme) using oligo (dT) and random hexamers, then qRT-PCR analysis was performed on them, and then they were put through PCR and qPCR analysis. Real-time quantitative PCR was carried out using ChamQ SYBR qPCR Master Mix (Vazyme) and either a 7900HT Fast Real-Time PCR System or an ABI Prism 7900HT Real-Time PCR System (Applied Biosystems). The relative expression of genes was quantified to GAPDH. The primer sequences were presented as follows: KDELR3 5′-TCCAGTCAATTGGCCTTTCC-3′ (forward) and 5′-CCATTTGACCAAGTGAATGC-3′ (reverse) and GAPDH 5′-GGAGGGAATCCTCCAAAT-3′ and 5′-GGCTGTGTCACTTCTCCTAGG-3′.

2.3. Data Resource and Preprocessing. The GDC Data Transfer Tool was used to retrieve the RNA expression profiles of 80 UM patients from TCGA database in FPKM format. In addition, mRNA and lncRNA expression data were also retrieved. On the UCSC Xena website, the pertinent clinico-pathological characteristics, such as sex, age, and cancer stage, were retrieved. Table 1 contains an in-depth presentation of the clinical features.

2.4. Functional Enrichment Analysis. We separated the samples from TCGA datasets into two groups based on the median expression level of KDELR3 and screened the dysregulated genes between the two groups using the “limma” program [23]. This was done so that we could gain a deeper understanding of the underlying mechanism of KDELR3. Then, we examined the genes in the two groups using the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) assays to see if they were abundant in significant biological processes. Then, we used the "http://org.Hs.eh.db" package to convert the gene symbols into Entrez IDs, and we used the “cluster Profiler,” “ggplot2,” and “enrich plot” packages to conduct a pathway enrichment analysis for the DEGs based on the GO database and KEGG. This was done by combining the results of the pathway enrichment analysis with the DEGs. After applying the false discovery rate (FDR) approach, the P values were recalculated, and significantly enriched pathways were determined to have an FDR of 0.25 or lower.

2.5. Tumor-Infiltrating Immune Cells (TICs) Profile. Using the LM22 signature, the CIBERSORT algorithm was utilized to conduct an analysis of the percentage of immune cells that had penetrated the tumor microenvironment (TME) [24]. The LM22 signature, which consists of 547 genes, was utilized to detect 22 different types of immune cells that had
infiltrated the tissue. In addition, we investigated the difference between KDELR3 expression and the immune cells that had penetrated the TME by performing difference and correlation analysis.

2.6. Correlation Analysis. The Cancer Regulome Explorer (http://explorer.cancerregulome.org/) enables users to search, filter, and visualize analytical results generated from TCGA data and explore associations among heterogeneous features. On the chromosomal level, we utilized it to display the expression of KDELR3 as well as its association with other variables that are associated with malignancies. In order to investigate the degree of association that exists between KDELR3 expression levels and clinicopathological characteristics, both the chi-square and t-tests were carried out. Spearman's coefficient was utilized in order to carry out the correlation study. In order to investigate the nature of the connection that exists between KDELR3 expression levels and clinicopathological characteristics, we utilized RT-PCR to investigate the level of KDELR3 in D78 cells and four different UM cell lines. We discovered that the level of KDELR3 expression was noticeably elevated in UM cells in comparison to D78 cells (Figure 1(a)). Nevertheless, TCGA datasets did not contain normal uveal specimens, suggesting that it could serve as a tumor promoter in the progression of diverse tumors as well as the normal tissues. Data from TCGA datasets showed that KDELR3 mRNA expression was distinctly higher in ACC, BLCA, BRCA, CESC, CHOL, COAD, DLBC, ESCA, GBM, HNSC, KIRP, LIHC, LUAD, LUSC, OV, PAAD, PRAD, PEAD, SARC, SKCM, STAD, THCA, THYM, UCEC, and UCS tumor specimens compared to that in normal specimens, suggesting that it could serve as a tumor promoter in the progression of diverse tumors (Figure 1(b)). Nevertheless, TCGA datasets did not contain any normal uveal specimens. Therefore, it is unknown whether KDELR3 demonstrated a dysregulated behavior in UM. Therefore, we utilized RT-PCR to investigate the level of KDELR3 in D78 cells and four different UM cell lines. We discovered that the level of KDELR3 expression was noticeably elevated in UM cells in comparison to D78 cells (Figure 1(b)).

2.7. IC50 Score. When determining the efficacy of a medicine or the response of a sample to treatment, one of the most essential indicators to look at is the half-maximal inhibitory concentration, also known as the IC50. The sample-based transcriptome, which makes use of the Genomics of Drug Sensitivity in Cancer (GDSC) database, which is the biggest publicly available pharmacogenomics resource, can predict the response of each sample to the targeting and/or immuno-therapy of UM.

2.8. Statistical Analysis. Statistical analysis was performed in R v. 4.0.2 (R Core Team, Massachusetts, USA) and GraphPad Prism v. 8.01 (GraphPad Software, La Jolla, CA, USA). The Wilcoxon rank-sum test was utilized in order to carry out analyses on box plots. Spearman's coefficient was utilized in order to carry out the correlation study. In order to investigate the nature of the connection that exists between KDELR3 expression levels and clinicopathological characteristics, the Wilcoxon rank-sum test was utilized in order to carry out analyses on box plots. Spearman’s coefficient was utilized in order to carry out the correlation study. In order to investigate the nature of the connection that exists between KDELR3 expression levels and clinicopathological characteristics, both the chi-square and t-tests were carried out. The Kaplan-Meier method was utilized in the construction of the survival curves (log-rank test). Survival data were evaluated through the univariate and multivariate Cox regression analysis. A $p < 0.05$ was deemed to be statistically significant.

3. Results

3.1. The mRNA Expression of KDELR3 in Cancers. In order to determine whether or not KDELR3 expression was correlated with cancer, we analyzed its levels in a variety of tumors as well as the normal tissues. Data from TCGA datasets showed that KDELR3 mRNA expression was distinctly higher in ACC, BLCA, BRCA, CESC, CHOL, COAD, DLBC, ESCA, GBM, HNSC, KIRP, LIHC, LUAD, LUSC, OV, PAAD, PRAD, PEAD, SARC, SKCM, STAD, THCA, THYM, UCEC, and UCS tumor specimens compared to that in normal specimens, suggesting that it could serve as a tumor promoter in the progression of diverse tumors (Figure 1(a)). Nevertheless, TCGA datasets did not contain any normal uveal specimens. Therefore, it is unknown whether KDELR3 demonstrated a dysregulated behavior in UM. Therefore, we utilized RT-PCR to investigate the level of KDELR3 in D78 cells and four different UM cell lines. We discovered that the level of KDELR3 expression was noticeably elevated in UM cells in comparison to D78 cells (Figure 1(b)).

3.2. Correlation of KDELR3 Expression with Clinicopathological Features. Further investigation into the relationship between KDELR3 and the clinicopathological features of UM was carried out so that we could determine the clinical significance of KDELR3 in UM. The patients diagnosed with UM were separated into two groups based on the mean expression of KDELR3 (high KDELR3 expression group and low KDELR3 expression group). As exhibited in Table 1, our investigation revealed that the level of KDELR3 was not connected to any clinical parameters, including age, gender, or stage ($p > 0.05$).

3.3. The Prognostic Value of KDELR3 Expression in UM. After that, we used the Kaplan-Meier method to determine whether or not the levels of KDELR3 expression can accurately predict the prognosis of patients with UM. Patients who had high levels of KDELR3 expression had a shorter overall survival (Figure 2(a), $p < 0.001$) and disease-free
Figure 1: KDELR3 expression levels in human cancers. (a) Using data from TCGA database, GEPIA was able to assess the levels of KDELR3 expression in a variety of tumor types. (b) RT-PCR was utilized in order to investigate whether KDELR3 was expressed in MUM-2C, OCM-1A, MUM-2B, C918, and D78.

Figure 2: Prognostic value of KDELR3 expression in UM patients. (a, b) In TCGA datasets, Kaplan-Meier survival curves and log-rank tests were performed on high-risk and low-risk score groups. (c) The AUC for 1-, 2-, and 3-year overall survival in TCGA datasets.
survival (Figure 2(b), \( p < 0.001 \)) than those who had low levels of KDELR3 expression. These findings were demonstrated by statistical analysis. Time-dependent ROC analysis indicated the prognostic accuracies were 0.798 at 1 year, 0.888 at 3 years, and 0.887 at 5 years, respectively (Figure 2(c)). In order to assess whether the KDELR3 expression level was an independent factor for prognostic prediction in UM patients, both univariate and multivariate analyses were carried out. We observed that KDELR3 expression was an independent prognostic factor for overall survival (HR = 13.397; 95% CI: 3.931-45.657; \( p < 0.001 \), Table 2) and disease-free survival (HR = 17.116; 95% CI: 3.961-73.971; \( p < 0.001 \), Table 3) in patients with UM.

### Table 2: Univariate and multivariate analysis of the associations of overall survival with various clinicopathologic parameters and KDELR3 expression in uveal melanoma patients.

| Characteristics | Total (N) | Univariate analysis | Multivariate analysis |
|-----------------|-----------|---------------------|-----------------------|
|                 |           | Hazard ratio (95% CI) | \( p \) value | Hazard ratio (95% CI) | \( p \) value |
| Pathologic T stage | 80 |  |  |
| T2 | 14 | Reference |  |
| T3 | 32 | 3.138 (0.401-24.558) | 0.276 |  |
| T4 | 34 | 4.572 (0.590-35.428) | 0.146 |  |
| Pathologic N stage | 79 |  |  |
| N0 | 52 | Reference |  |
| NX | 27 | 0.890 (0.360-2.198) | 0.800 |  |
| Pathologic M stage | 78 |  |  |
| M0 | 51 | Reference |  |
| M1 and MX | 27 | 0.924 (0.373-2.287) | 0.865 |  |
| Pathologic stage | 79 |  |  |
| Stage II | 39 | Reference |  |
| Stage III and stage IV | 40 | 1.502 (0.629-3.585) | 0.360 |  |
| Age | 80 |  |  |
| \( \leq 60 \) | 40 | Reference |  |
| >60 | 40 | 2.123 (0.914-4.933) | 0.080 | 2.528 (1.055-6.061) | 0.038 |
| Gender | 80 |  |  |
| Female | 35 | Reference |  |
| Male | 45 | 1.542 (0.651-3.652) | 0.325 |  |
| KDELR3 | 80 |  |  |
| Low | 40 | Reference |  |
| High | 40 | 12.517 (3.685-42.512) | \textless 0.001 | 13.397 (3.931-45.657) | \textless 0.001 |

3.5. Correlation Analysis between KDELR3 Expression and Infiltrating Immune Cells. TILCs are a crucial component of the intricate microenvironment that plays a role in regulating the development and progression of numerous malignancies [25, 26]. Survival rates from cancer can be accurately predicted based on factors such as the number of lymphocytes that infiltrate the tumor and their activity level. As a result, we investigated whether or not there was a connection between immune cell infiltration and KDELR3 expression. We explored the relationship of KDELR3 expression and immune infiltration level based on CIBERSORT in order to identify whether KDELR3 expression was connected with the immune infiltration level in a variety of malignancies. The results indicated that KDELR3 expression was positively associated with macrophage M1, T cell CD8, T cell follicular helper, dendritic cell resting, and T cell CD4 memory activated, while negatively associated with NK cell resting, B cell naïve, eosinophils, neutrophils,
monocytes, mast cell resting, and T cell CD4 memory resting (Figure 4). According to the results of our research, the level of immune infiltration in UM was directly proportional to the amount of KDELR3 expression.

3.6. Correlation Analysis between KDELR3 Expression and Immune Checkpoint Molecules in UM. Subsequently, we determined the linear correlation between the expression of immune checkpoint related genes (CD86, PDCD1, CD48, CD80, CD276, TNFSF18, TNFRSF8, and TNFRSF18) and risk scores using Spearman’s rank correlation coefficient. These genes include CD86, PDCD1, CD48, CD80, CD276, TNFSF18, TNFRSF8, and TNFRSF18. The results indicated that the expression of immunosuppression-related genes had positive correlation with KDELR3 expression in TCGA datasets (Figure 5).

3.7. IC50 Score. When determining how well patients may respond to targeted medication therapy, IC50 is an essential metric to use [27, 28]. We were able to predict changes in the IC50 scores of chemotherapeutic drugs between different KDELR3 expression groups by using data from GDSC. The IC50 of AP-24534, BHG712, bleomycin, camptothecin, cisplatin, cytarabine, GSK1070916, and tipifarnib was higher in the KDELR3 high-expression group (Figure 6). Therefore, these data demonstrate that there was a statistically significant difference in the distribution of IC50 values for targeted drugs among the different KDELR3 expression groups.

4. Discussion

UM is a malignant primary intraocular tumor that affects adults at a higher rate than any other type of malignant primary intraocular tumor [29]. The majority of UM are often treated with surgery or radiotherapy, which typically results in survival rates that are comparable over the short term [30, 31]. Because of its unique biology and clinical behavior, around fifty percent of patients will be given a bad prognosis, which may include disease recurrence and dissemination. To date, conventional methods have not been able to provide a survival benefit or exact prognostic prediction for these patients. On the other hand, more recent systemic treatments, in particular immunotherapies and targeted therapy, have dramatically improved patient survival. Nevertheless, the discovery of novel prognostic indicators was of utmost significance for patients diagnosed with UM. In this work, we conducted a retrospective analysis to choose biomarkers that linked with the immunological milieu of the tumor in order to predict prognosis and identify the segment of the population that would benefit the most from immune checkpoints.

The role of KDELR3, which was only recently shown to be associated with tumors, was seldom ever mentioned. The
KDELR3 gene is a member of the KDEL endoplasmic reticulum protein retention receptor family. Its product, KDELR3, is translated into proteins. According to the findings of the study carried out by Marie and colleagues, the inhibition of KDELR3 led to a reduction in the amount of mRNA expression of KDELR3 was shown to be significantly greater than that in the control group in order to gain a deeper understanding of the possible role that KDELR3 played in the progression of tumors. Our findings suggested that KDELR3 may play an important role in the progression of neurodegeneration—multiple diseases, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, prion disease, and thermogenesis.

Cancer tissues consist of not only malignant neoplastic cells but also immune cells, fibroblasts, endothelial cells, and an abundant collection of cytokines, chemokines, and growth factors [33]. The TME is formed by these components and their complex interaction with one another. The various cellular compartments that make up the TME are able to critically regulate tumorigenesis, which is essential not only to tumor initiation, malignant progression, and metastasis but also to response to therapy [34, 35]. In the TME, the majority of host cells that are drawn to and activated are immune cells. Determining appropriate immunotherapy treatment plans for cancer patients now relies significantly on the detection of immune cells that can serve as biomarkers in the cancer immunological microenvironment. The quantity of immune cells and how they are distributed is the single most critical element in determining the eventual course of a tumor, including whether or not it will inhibit or promote carcinogenesis, cell metastasis, cell migration, and tumor angiogenesis [36, 37]. Nevertheless,
the immunological microenvironment in the many forms of cancer is intricate and heterogeneous. In this study, we found that KDELR3 expression was positively associated with macrophage M1, T cell CD8, T cell follicular helper, dendritic cell resting, and T cell CD4 memory activated, while negatively associated with NK cell resting, B cell naive, eosinophils, neutrophils, monocytes, mast cell resting, and T cell CD4 memory resting. According to the findings that we obtained, the level of immune infiltration in UM was directly proportional to the amount of KDELR3 expression. In recent years, immune checkpoint blockade therapy has emerged as one of the most important immunotherapies for the treatment of cancers. This therapy is credited for fundamentally altering the landscape of cancer treatment. Inducing a long-lasting anticancer response and removing a block in the immune system are the goal of immunotherapy that blocks immunological checkpoints [38, 39]. In addition, we discovered that the expression of genes linked to immunosuppression had a positive connection with the expression of KDELR3 in TCGA datasets. When determining how well patients may respond to targeted medication therapy, IC50 is an essential metric to use. We were able to predict changes in the IC50 scores of chemotherapeutic drugs between different KDELR3 expression groups by using data from GDSC. The IC50 of AP-24534, BHG712, bleomycin, camptothecin, cisplatin, cytarabine, GSK1070916, and tipifarnib was higher in the KDELR3 high-expression group. Consequently, these findings showed that the IC50 distributions of targeted drugs in distinct KDELR3 expression groups were statistically significant.

However, despite the fact that we conducted an exhaustive and methodical study on KDELR3, we found nothing. This study has certain caveats and restrictions to it. First, the findings were based on data that was collected in the past, and more data collected in the present was required to prove the clinical relevance of it. Second, experiments in vivo and in vitro are required to validate our findings about the possible functions of KDELR3. If these experiments are successful, the credibility of our findings will be significantly increased. Third, despite the fact that KDELR3 expression was highly connected to immune cell infiltration and the prognosis of human malignancies, we do not have any direct proof that KDELR3 played a role in immune infiltration and hence influenced the prognosis. Therefore, the methods via which KDELR3 participated in immune modulation are still a mystery, and the precise pathway needed additional research.

5. Conclusions

Our research contributed to a better understanding of the potential function of KDELR3 mRNA in tumor immunology as well as its relevance as a prognostic indicator. It was found that the levels of KDELR3 mRNA connected with both the prognosis and the immune infiltration levels in UM, indicating that it can be employed as a biomarker for
Figure 5: The differential expression of immune checkpoint molecules in TCGA cohorts between the high-risk group and the low-risk group.

Figure 6: Distribution of IC50 scores of targeted drugs in different KDELR3 expression groups via ACLBI website.
predicting the outcome of the disease. It is necessary to investigate the possibility that KDELR3 inhibitors would cause interference with immune cells.

**Data Availability**

The data used to support the findings of this study are included within the article. Further inquiries can be directed to the corresponding author.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**References**

[1] M. J. Jager, C. L. Shields, C. M. Cebulla et al., “Uveal melanoma,” *Nature Reviews. Disease Primers*, vol. 6, no. 1, p. 24, 2020.

[2] K. N. Smit, M. J. Jager, A. de Klein, and E. Kiliç, “Uveal melanoma: towards a molecular understanding,” *Progress in Retinal and Eye Research*, vol. 75, article 100800, 2020.

[3] A. Amaro, R. Gangemi, F. Piaggio et al., “The biology of uveal melanoma,” *Cancer Metastasis Reviews*, vol. 36, no. 1, pp. 109–140, 2017.

[4] I. H. Bronkhorst and M. J. Jager, “Uveal melanoma: the inflammatory microenvironment,” *Journal of Innate Immunity*, vol. 4, no. 5-6, pp. 454–462, 2012.

[5] C. Rodriguez-Vidal, D. Fernandez-Diaz, B. Fernandez-Martí et al., “Treatment of metastatic uveal melanoma: systematic review,” *Cancers (Basel)*, vol. 12, no. 9, p. 2557, 2020.

[6] R. S. Seedor, M. Orloff, and T. Sato, “Genetic landscape and emerging therapies in uveal melanoma,” *Cancers (Basel)*, vol. 13, no. 21, p. 5503, 2021.

[7] D. Martinez-Perez, D. Viñal, I. Solares, E. Espinosa, and J. Feliu, “Gp-100 as a novel therapeutic target in uveal melanoma,” *Cancers (Basel)*, vol. 13, no. 23, p. 5968, 2021.

[8] Y. Bai, W. Qi, L. Liu et al., “Identification of seven-gene hypoxia signature for predicting overall survival of hepatocellular carcinoma,” *Frontiers in Genetics*, vol. 12, article 637418, 2021.

[9] J. Parkin and B. Cohen, “An overview of the immune system,” *Lancet*, vol. 357, no. 9270, pp. 1777–1789, 2001.

[10] M. Huse, “Mechanical forces in the immune system,” *Nature Reviews. Immunology*, vol. 7, no. 11, pp. 679–690, 2017.

[11] D. P. Huston, “The biology of the immune system,” *JAMA*, vol. 278, no. 22, pp. 1804–1814, 1997.

[12] M. Calvo, J. M. Dawes, and D. L. Bennett, “The role of the immune system in the generation of neuropathic pain,” *Lancet Neurology*, vol. 11, no. 7, pp. 629–642, 2012.

[13] A. Sáez-Cirión and N. Manel, “Immune responses to retroviruses,” *Annual Review of Immunology*, vol. 36, no. 1, pp. 193–220, 2018.

[14] L. Tagliaferri, V. Lancellotta, B. Fionda et al., “Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review,” *Human Vaccines & Immunotherapeutics*, vol. 18, no. 3, p. 1903827, 2022.

[15] M. E. Ritchie, B. Phipson, D. Wu et al., “limma powers differential expression analyses for RNA-sequencing and microarray studies,” *Nucleic Acids Research*, vol. 43, no. 7, article e47, 2015.

[16] A. M. Newman, C. L. Liu, M. R. Green et al., “Robust enumeration of cell subsets from tissue expression profiles,” *Nature Methods*, vol. 12, no. 5, pp. 453–457, 2015.

[17] A. Byrne, P. Savas, S. Sant et al., “Tissue-resident memory T cells in breast cancer control and immunotherapy responses,” *Nature Reviews. Clinical Oncology*, vol. 17, no. 6, pp. 341–348, 2020.

[18] E. Kolaczkowska and P. Kubes, “Neutrophil recruitment and function in health and inflammation,” *Nature Reviews. Immunology*, vol. 13, no. 3, pp. 159–175, 2013.

[19] R. Roy, M. Tiwari, G. Donelli, and V. Tiwari, “Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action,” *Virology*, vol. 9, no. 1, pp. 522–554, 2018.

[20] S. M. Clemente, O. H. Martinez-Costa, M. Monsalve, and A. K. Samhan-Arias, “Targeting lipid peroxidation for cancer treatment,” *Molecules*, vol. 25, no. 21, p. 5144, 2020.

[21] C. Chattopadhyay, D. W. Kim, D. S. Gombos et al., “Uveal melanoma: from diagnosis to treatment and the science in between,” *Cancer*, vol. 122, no. 15, pp. 2299–2312, 2016.

[22] K. K. Tsai, K. B. Bollin, and S. P. Patel, “Obstacles to improving outcomes in the treatment of uveal melanoma,” *Cancer*, vol. 124, no. 13, pp. 2693–2703, 2018.

[23] S. Khan and R. D. Carvajal, “Novel approaches to the systemic management of uveal melanoma,” *Current Oncology Reports*, vol. 22, no. 10, p. 104, 2020.

[24] K. L. Marie, A. Sassano, H. H. Yang et al., “Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis,” *Nature Communications*, vol. 11, no. 1, p. 333, 2020.

[25] S. Gampala and J. Y. Yang, “Hedgehog Pathway Inhibitors against Tumor Microenvironment,” *Cell*, vol. 10, no. 11, p. 3135, 2021.
[34] X. Li and J. Wang, "Mechanical tumor microenvironment and transduction: cytoskeleton mediates cancer cell invasion and metastasis," *International Journal of Biological Sciences*, vol. 16, no. 12, pp. 2014–2028, 2020.

[35] X. Fu, Y. He, M. Li, Z. Huang, and M. Najafi, "Targeting of the tumor microenvironment by curcumin," *BioFactors*, vol. 47, no. 6, pp. 914–932, 2021.

[36] M. Kienzl, J. Kargl, and R. Schicho, "The immune endocannabinoïd system of the tumor microenvironment," *International Journal of Molecular Sciences*, vol. 21, no. 23, p. 8929, 2020.

[37] H. Jang, E. H. Kim, S. G. Chi, S. H. Kim, and Y. Yang, "Nanoparticles targeting innate immune cells in tumor microenvironment," *International Journal of Molecular Sciences*, vol. 22, no. 18, p. 10009, 2021.

[38] M. G. Netea, L. A. Joosten, E. Latz et al., "Trained immunity: a program of innate immune memory in health and disease," *Science*, vol. 352, no. 6284, p. aaf1098, 2016.

[39] A. Hosseini, V. Hashemi, N. Shomali et al., "Innate and adaptive immune responses against coronavirus," *Biomedicine & Pharmacotherapy*, vol. 132, article 110859, 2020.